|Items||Size （2mg）||Size（5mg X 2）|
|Particle size||2 μm||2 μm|
|Physical appearance||Powder mixture||Powder mixture|
|Amount of Coupled Protein||>1000 pmol (49 μg) Nucleocapsid protein/mg beads||>1000 pmol (49 μg) Nucleocapsid protein/mg beads|
|Binding Capacity||>130 pmol (20 μg) Anti-Nucleocapsid antibody/mg beads||>130 pmol (20 μg) Anti-Nucleocapsid antibody/mg beads|
|Formulation||PBS, pH7.4, with 10% Trehalose||PBS, pH7.4, with 10% Trehalose|
|Reconstitution||2 mL ultrapure water (1 mg beads/mL)||5 mL ultrapure water (1 mg beads/mL)|
Upon receipt, please store the Beads at -20℃ for 1 year in lyophilized state.
Please avoid more than 3 freeze-thaw cycles. Immediate use after reconstitution is highly recommended.
1. Resuspend the lyophilized beads by adding the buffer of choice.
2. Add analyte to the suspension, mix and incubate to enable specific binding of the beads and the target protein.
3. Magnetize beads, remove supernatant, and wash unbound protein fractions to capture target protein-bound beads.
4. Wash, magnetize the beads and collect purified target protein for use in downstream applications.
Immobilized 49 μg SARS-CoV-2 Nucleocapsid protein to 1 mg Beads can bind the Anti-SARS-CoV-2 Nucleocapsid Antibody with an EC50 of 0.6712 μg/mL (QC tested).
Accelerated stability test. After placing the lyophilized beads at 37℃ for 7 days, binding activity between the SARS-CoV-2 Nucleocapsid Protein-coupled Magnetic Beads (Cat.No. MBS-K017) and the Anti-SARS-CoV-2 Nucleocapsid Antibody showed little deviation from the unaccelerated sample (%RSD<10%). Data were measured on day 0, 3, 7 respectively.
Freeze-thaw stability test. After different freeze-thaw cycles, binding activity between the SARS-CoV-2 Nucleocapsid Protein-coupled Magnetic Beads (Cat.No. MBS-K017) and the Anti-SARS-CoV-2 Nucleocapsid Antibody showed little deviation from the unfreeze-thaw sample (%RSD<10%). Three freeze-thaw cycles were performed.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.